Kapuscinski M, Green M, Sinha S N, Shepherd J J, Shulkes A
Department of Surgery, University of Melbourne, Austin Hospital, Victoria, Australia.
Clin Endocrinol (Oxf). 1993 Jul;39(1):51-8. doi: 10.1111/j.1365-2265.1993.tb01750.x.
C-terminal amidation is an essential processing step towards bioactivation of many peptides including gastrin. This reaction is catalysed by peptidylglycine alpha-amidating mono-oxygenase (PAM, EC 1.14.17.3) which converts the glycine extended precursors on their carboxyl termini to the des-glycine amidated peptide products. In the case of gastrin, most of the amidation is thought to occur in the antrum. However substantial quantities of glycine extended gastrin and PAM are present in plasma. It is unclear whether circulating PAM reflects the secretory activity of the gastrin secreting cell or whether PAM is involved in the postsecretory processing of gastrin. The aim of the present study was to relate the circulating amidation activity to the plasma concentrations of glycine extended and amidated gastrins.
Plasma PAM, gastrin-amide and gastrin-gly were measured in subjects with different gastrin secretory status: healthy subjects basally and following a meal, members of families with multiple endocrine neoplasia type 1 (MEN-1) with normal and high plasma gastrin, and patients with hypergastrinaemic atrophic gastritis.
Patients with MEN-1 and hypergastrinaemia tended to have a higher plasma PAM activity than MEN-1 subjects with normal circulating G-NH2 indicating a cosecretion of hormone and PAM. However in contradistinction to patients with medullary thyroid carcinoma, PAM activity does not appear to be a useful tumour marker of gastrinoma. Hypergastrinaemia from a non-tumour source (hypergastrinaemic non-atrophic gastritis) was associated with a lower plasma PAM activity than in normal subjects and may reflect the secretion of a greater proportion of already amidated gastrin. In general, there was no relationship between plasma PAM activity and the ratio of amidated to non-amidated gastrin suggesting that circulating PAM was not involved in the amidation of gastrin. Feeding increased circulating gastrin but had no effect on plasma PAM activity.
The results support the view that gastrin is amidated at the site of its synthesis and that hypergastrinaemia is associated with elevated plasma amidating enzyme activity only when the gastrin originates from tumour sources.
C末端酰胺化是许多肽(包括胃泌素)生物活化的关键加工步骤。该反应由肽基甘氨酸α-酰胺化单加氧酶(PAM,EC 1.14.17.3)催化,它将羧基末端的甘氨酸延伸前体转化为去甘氨酸酰胺化肽产物。就胃泌素而言,大多数酰胺化被认为发生在胃窦。然而,血浆中存在大量的甘氨酸延伸胃泌素和PAM。尚不清楚循环中的PAM是反映胃泌素分泌细胞的分泌活性,还是PAM参与胃泌素的分泌后加工。本研究的目的是将循环酰胺化活性与甘氨酸延伸型和酰胺化胃泌素的血浆浓度联系起来。
在具有不同胃泌素分泌状态的受试者中测量血浆PAM、胃泌素酰胺和胃泌素甘氨酸:基础状态及餐后的健康受试者、血浆胃泌素正常和升高的1型多发性内分泌腺瘤(MEN-1)家族成员,以及高胃泌素血症性萎缩性胃炎患者。
MEN-1和高胃泌素血症患者的血浆PAM活性往往高于循环G-NH2正常的MEN-1受试者,表明激素和PAM共同分泌。然而,与甲状腺髓样癌患者不同,PAM活性似乎不是胃泌素瘤的有用肿瘤标志物。非肿瘤来源的高胃泌素血症(高胃泌素血症性非萎缩性胃炎)与血浆PAM活性低于正常受试者有关,这可能反映了已酰胺化胃泌素分泌比例更高。一般来说,血浆PAM活性与酰胺化胃泌素与未酰胺化胃泌素的比例之间没有关系,这表明循环中的PAM不参与胃泌素的酰胺化。进食增加了循环胃泌素,但对血浆PAM活性没有影响。
结果支持以下观点,即胃泌素在其合成部位进行酰胺化,并且仅当胃泌素来源于肿瘤时,高胃泌素血症才与血浆酰胺化酶活性升高有关。